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Introduction
With over 6 million Americans living with Alzheimer’s disease 
(AD) in 2021, AD is the most common neurodegenerative 
disease that eventually leads to a loss of cognition. The 
accumulation of proteins including tau tangles and amyloid 
plaques in the brain leads to a cognitive decline and symptoms 
of dementia by catalyzing neuronal cell death. These 
accumulations of proteins and their underlying mechanisms can 
occur years prior to an onset of symptoms, which makes it 
possible to have individuals with asymptomatic Alzheimer’s 
disease. For this project, I compared, through proteomic data 
analysis of data acquired by Johnson et. al., significant changes 
in protein abundance between control brain samples and 
asymptomatic Alzheimer’s brain samples and identified 
proteins and functional processes that may be involved in the 
initiation of the asymptomatic stage of Alzheimer’s disease. 
Materials and Methods
Figure 1. The data that was used in the proteomics analysis was acquired from 
asymptomatic Alzheimer’s brain samples and control brain samples. TMT based 
mass spectrometry was used to measure the relative abundance of proteins. These 
in-lab procedures were done by Johnson et. al. and published as public data. In our 
process of proteomic data analysis, we filtered this public data for significance 
meaning that there was a substantial difference in protein abundance between the 
control and asymptomatic samples. These significant proteins were then used in a 
GO analysis to show the biological implications of their change in abundance. This 
can help identify the neurological changes that occur as a result of the significant 
changing abundances of these specific proteins. 
Results
Figure 2. Volcano plot depicting the significantly increasing proteins, 
CNTNAP1, PLP1, CNTN2, QKI, SOD1, JAM3, that are involved in the 
myelination of neuronal cells affected by the asymptomatic stage of 
Alzheimer’s disease.
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Figure 5. GO analysis of the negatively differing significant proteins 
showed three proteins that effect DNA damage recognition and 
nucleotide-excision repair. It also showed three proteins that effect the 
regulation of stress induced neuron death increasing in the 
asymptomatic Alzheimer’s samples comparative to the control samples. 
These two groups of proteins recognize damage to the DNA helix and 
modulate the frequency of oxidative stress induced neuronal death 
respectively. The three proteins that increase DNA damage recognition, 
COPS6, COPS3, PARP1, increase at a fold enrichment of 34.89 from 
an expected value of 0.09. The three proteins that increase the 
regulation of neuronal death through oxidative stress, APP, LANCL1, 
PARP1 increase at a fold enrichment of 32.10 from an expected value 
of 0.09. The protein PARP1 increases in both categories indicating the 
implication of DNA damage as the consequence of neuronal death. The 
increase of these proteins depicts the cellular response to neuronal 
death. 
Figure 4. GO analysis of the negatively differing significant proteins 
between control samples and asymptomatic Alzheimer’s disease 
samples (proteins that increase in abundance in the asymptomatic 
Alzheimer’s samples). Six proteins dealing with myelination increased 
in the asymptomatic Alzheimer’s samples. These six proteins, 
increased at a fold enrichment of 15.14 from an expected value of 0.4. 
Myelination proteins are associated with formation and maintenance 
of myelin sheaths around neurons, suggesting an increase in the cell’s 
effort to maintain the neuronal pathways through increased 
myelination during the progression of Alzheimer’s disease. 
Myelination DNA damage and oxidative stress response
The first step in the progression of Alzheimer’s disease is 
the asymptomatic stage. Analysis of the changing proteins 
at this stage relative to a healthy patient can give insight 
into what cellular changes lead to onset of disease. 
Proteomics allow for quantification and comparison of 
proteins that are changing between a control brain sample 
and a brain sample with asymptomatic Alzheimer’s disease. 
Significantly more proteins increase in abundance in the 
asymptomatic Alzheimer’s samples compared to the control 
samples, supporting the idea that the early progression of 
Alzheimer’s is due to at least some level of protein 
accumulation and that even at the beginning the rate of cell 
death is increasing. Further analysis into the proteins that 
are significantly changing can then be used to identify 
enriched biological functions in asymptomatic AD. In the 
case of asymptomatic AD, these processes include proteins 
dealing with myelination, DNA damage and oxidative 
repair. The increase in these proteins shows that cells are 
attempting to maintain myelination and slow the rate of 
cellular death in the asymptomatic stage, long before 
presenting with symptoms. The development of more 
proteomic analysis into the beginning stages of 
asymptomatic AD shows potential to reveal more proteins 
and functions that are increasing at the onset of the disease. 
Alzheimer’s disease can currently only be treated by the 
management of symptoms, and an increased understanding 
of these changes leading to an asymptomatic stage of AD 
will help in early detection and intervention. 
